Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Just a few days after Astellas Pharma formally unveiled its new five-year corporate strategic plan in Tokyo in late May, Naoki Okamura, the global drugmaker’s representative director, president and CEO, was in New York City walking through the architecture and vision behind it. During an interview with Pharmaceutical Executive in midtown Manhattan, Okamura pointed to a screen beside him, where the Astellas revenue outlook appeared as overlapping waves: the mature portfolio — anchored by cornerstone franchise Xtandi (co-marketed with Pfizer) — beginning to recede, five strategic brands already climbing and a developing pipeline expected to take the baton later in the decade.
